Mode
Text Size
Log in / Sign up
Phase 3 Completed N=40 Randomized Single-blind Treatment

Evaluation of Green Tea as Antioxidant Agent in Management of Oral Lichen Planus

Source: ClinicalTrials.gov NCT02329600 ↗
Enrolled (actual)
40
Serious AEs
0.0%
Results posted
Nov 2016
Primary outcomePrimary: Pain — 0; 4; 4.4 units on a scale
◆ Published Evidence
Highly cited
1,590citations · ~106 / year
Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications.
Biochemical pharmacology · 2011 · High-confidence link

Summary

The study included forty individuals divided into 3 groups. 10 control subjects, 15 oral lichen planus (OLP) patients who were treated with topical corticosteroids and 15 oral lichen planus (OLP) patients who were treated with topical corticosteroids and green tea tablets.

Linked Publications (5)

  • Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications.
    Biochemical pharmacology · 2011 · 1,590 citations · High-confidence link
  • Direct scavenging of nitric oxide and superoxide by green tea.
    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2002 · 362 citations · High-confidence link
  • Oxidative stress status and DNA damage in saliva of human subjects with oral lichen planus and oral squamous cell carcinoma.
    Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology · 2012 · 96 citations · High-confidence link
  • Decreased antioxidant enzyme expression and increased oxidative damage in erosive lichen planus of the vulva.
    BJOG : an international journal of obstetrics and gynaecology · 2005 · 41 citations · Open access · High-confidence link
  • Green tea consumption: an alternative approach to managing oral lichen planus.
    Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2012 · 30 citations · High-confidence link

Outcome Measures

OutcomeResultp-value
PRIMARY
Pain
0; 4; 4.4
SECONDARY
Salivary Total Oxidative Capacity
6.37; 58.41; 23.27

Eligibility Criteria

Inclusion Criteria

  • Patients presented with painful oral lichen planus lesions
  • Free of any visible oral lesions other than oral lichen planus
  • Free of any systemic diseases

Exclusion Criteria

  • Topical treatment or systemic therapy of OLP for one month before starting the study
  • Pregnant or breast feeding women
  • Smokers
  • Use of corticosteroids or other immunosuppressive drugs
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02329600) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search